Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31000749 | 1.00 | LMNA (0.53) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL2452367 | 1.00 | LMNA (0.53) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL13374285 | 1.00 | LMNA (0.53) | LMNANR1I2PTGS1ADRA1ABLM | |
| Hydrochloric Acid SCHEMBL4205224 | 0.98 | LMNA (0.51) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL10501729 | 0.82 | GRM8 (0.39) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL751652 | 0.81 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL8528068 | 0.81 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL443815 | 0.81 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL4086543 | 0.81 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL4728748 | 0.81 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851119-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2020-05-21 | — | — | US | disclosed |
| EP-3194359-B1 | BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDS | INTREXON CORP (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10570158-B2 | Boron-containing diacylhydrazine compounds | INTREXON CORPORATION (US) | 2020-02-25 | — | — | US | disclosed |
| US-10464951-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180201628-A1 | Boron-Containing Diacylhydrazine Compounds | INTREXON CORP (US) | 2018-07-19 | — | — | US | disclosed |
| EP-2970106-B1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9944659-B2 | Boron-containing diacylhydrazine compounds | INTREXON CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| EP-3194359-A1 | BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDS | Intrexon Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-1307214-A1 | HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS | INVITROGEN CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1076563-A4 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2003-04-23 | — | — | EP | disclosed |
| CN-1379785-A | Caspase inhibitors for the treatment and prevention of chemotherapy and radiotherapy induced cell death | CYTOVIA INC (US) | 2002-11-13 | — | — | CN | disclosed |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | INVITROGEN CORPORATION | 2002-10-24 | — | — | US | disclosed |
| EP-1220869-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | Cytovia, Inc. (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2002013848-A1 | HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS | INVITROGEN CORPORATION (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001027140-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | CYTOVIA, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-1076563-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6153591-A | PROTECTING NERVOUS SYSTEM FOLLOWING FOCAL ISCHEMIA AND GLOBAL ISCHEMIA; ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PRION DISEASES, PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, ALOPACIA, RHEUMATOID ARTHRITIS | CYTOVIA, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999047154-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464951-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | LMNA 4772/4885NR1I2 943/4885PTGS1 4694/4885 |
| US-20180201628-A1 | Boron-Containing Diacylhydrazine Compounds | BRDT, CD22, BCR | LMNA 4750/4885NR1I2 1203/4885PTGS1 4778/4885 |
| US-10851119-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | LMNA 4772/4885NR1I2 943/4885PTGS1 4694/4885 |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | CD22, BRDT, BCR | LMNA 4772/4885NR1I2 943/4885PTGS1 4694/4885 |
| US-10570158-B2 | Boron-containing diacylhydrazine compounds | BRDT, CD22, BCR | LMNA 4750/4885NR1I2 1203/4885PTGS1 4778/4885 |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | LMNA 4772/4885NR1I2 943/4885PTGS1 4694/4885 |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | CD44, HLA-C, HLA-A | LMNA 1264/4885NR1I2 3783/4885PTGS1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.